Imunon, Inc (IMNN) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Imunon, Inc stock $0.51, price $0.63, that is 19.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Imunon, Inc
IMNN · USExpensive (fair value 19% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.6300 – $185.44 · fair‑value band $0.3823 – $0.6371 · the $0.6300 price screens above the $0.5097 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Imunon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
Show moreShow less
The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Stock analysis
Imunon, Inc (IMNN) currently trades at $0.6300, while our estimate is $0.5097, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.3823 (bear) to $0.6371 (bull), the price of $0.6300 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Imunon, Inc reported revenue of $0 in FY2025 versus $500K in FY2021. Reported net income was −$14.5M in FY2025.
Key figures
Market cap $4.1M Micro · P/S ratio 32.6 · EPS (TTM) $−3.31 · Return on equity −430% · Return on assets (EBIT) −99.4% (5-year average) · Revenue (TTM) $125K · Free cash flow −$14.2M · Net cash $7.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 85% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −19%, IMNN screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director sold shares worth $38,127 and none bought.
- SaleSusan EylwardGeneral Counsel and Corp Sec6× since Jun 29, 2026: 22,385 shares, avg. $1.70$38,127Aug 31, 2026
Plus 57 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Imunon, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs IMNN |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs IMNN |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IMNN |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs IMNN |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs IMNN |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IMNN |
| Moderna, Inc MRNA | $223.37 | $135.64 | −39% | vs IMNN |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs IMNN |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IMNN |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs IMNN |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Imunon, Inc (IMNN) overvalued or undervalued?
What is the fair value of IMNN?
What is the quality score of IMNN?
What is the price target for Imunon, Inc (IMNN)?
What is the Imunon, Inc stock forecast for 2026?
What is the revenue of Imunon, Inc (IMNN)?
What is the intrinsic value of Imunon, Inc (IMNN)?
Is Imunon, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IMNN?
How much is Imunon, Inc worth?
What do the bullish and bearish scenarios say about IMNN?
What is the PEG ratio of IMNN?
How solid is the balance sheet of Imunon, Inc (IMNN)?
How far is IMNN from its 52-week high?
Which stocks are comparable to Imunon, Inc?
Is Imunon, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Imunon, Inc (IMNN)?
What should I pay attention to with Imunon, Inc right now?
Key figures of Imunon, Inc
How large is the market capitalisation of Imunon, Inc (IMNN)?
What is the P/S ratio of Imunon, Inc (IMNN)?
What are the earnings per share of Imunon, Inc (IMNN)?
What is the return on equity of Imunon, Inc (IMNN)?
What is the EBIT return on assets of Imunon, Inc (IMNN)?
How much free cash flow does Imunon, Inc (IMNN) generate?
How much net cash does Imunon, Inc (IMNN) hold?
Watch Imunon, Inc in the live analysis
One click puts Imunon, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.